Erythropoietin hyporesponsiveness: From iron deficiency to iron overload

Kidney International, Supplement

Volumn 55, Issue 69, 1999, Pages

  Tarng, Der Cherng ^a   Huang, Tung Po ^b   Chen, Tzen Wen ^b   Yang, Wu Chang ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Anemia; Chronic renal failure; Dialysis; Iron supplementation; RHuEPO

Indexed keywords

ASCORBIC ACID; FERRITIN; IRON; PROTOPORPHYRIN ZINC; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ALUMINUM;

ADULT; ANEMIA; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DOSE RESPONSE; FEMALE; HEMATOCRIT; HEMOGLOBINOPATHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; REVIEW; UREMIA; BLOOD; HEMOLYSIS; INFECTION; INFLAMMATION; METABOLISM; THALASSEMIA;

ALUMINUM; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINOPATHIES; HEMOLYSIS; HUMANS; INFECTION; INFLAMMATION; IRON; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC; THALASSEMIA;

EID: 0032915659     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ki.4490858     Document Type: Review

References (123)

1. WINEARLS CG, OLIVER DO, PIPPERD MJ, REID C, DOWNING MR, COTES PM: Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 2:1175-1178, 1986
2. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
3. SCHAEFER RM, HÖRL H, MASSRY SG: Treatment of renal anemia with recombinant human erythropoietin. Am J Nephrol 9:353-362, 1989
4. EVANS RW: Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: A comparative analysis. Am J Kidney Dis 18(Suppl 1):62-70, 1991
5. TEMPLE RM, LANGAN SJ, DEARY IJ, WINNEY RJ: Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients. Nephrol Dial Transplant 7:240-245, 1992
6. MORENO F, ARACIL FJ, PÉREZ R, VALDERRÁBANO F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-renal anemia with erythropoietin. Am J Kidney Dis 27:548-556, 1996
7. MACDOUGALL IC, LEWIS NP, SAUNDERS MJ, COCHLIN DL, DAVIES ME, HUTTON RD, FOX KA, COLES GA, WILLIAMS JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335:489-493, 1990
8. ESCHBACH JW, AQUILING T, HALEY NR, FAN MH, BLAGG CR: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 38(Suppl 1):98-103, 1992
9. CANAUD B, BOULOUN C, RIVORY JP, TAIB J, GARRED LJ, FLORENCE P, MION C: Erythropoietin-induced changes in protein nutrition: Quantitative assessment by urea kinetic modeling analysis. Blood Purif 8:301-308, 1990
10. BÁRÁNY P, PETTERSSON E, AHLBERG M, HULTMAN E, BERGSTRÖM J: Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 35:270-279, 1991
11. TARNG DC, HUANG TP, DOONG, TI: Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin. Nephron 78:253-259, 1998
12. STIVELMAN JC: Resistance to recombinant human erythropoietin therapy: A real clinical entity? Semin Nephrol 9(Suppl 2):8-11, 1989
13. DRUEKE TB: Resistance to recombinant human erythropoietin in hemodialysis. Am J Nephrol 10(Suppl 2):34-39, 1990
14. MACDOUGALL IC: Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant 10:607-614, 1995
15. BECKER BN, KOURY MJ: Resistance to erythropoietin in dialysis patients: Factors that decrease erythropoietin responsiveness. Dial Transplant 22:686-692, 1992
16. HÖRL WH, CAVILL I, COVE-SMITH R, ESCHBACH JW, MACDOUGALL IC, SALMONSON T, SCHAEFER RM, SUNDER-PLASSMANN G: How to get the best out of r-HuEPO? Nephrol Dial Transplant 10(Suppl 21:92-95, 1995
17. MACDOUGALL IC: Poor response to erythropoietin should be fully investigated and treated. BMJ 310:1424-1425, 1995
18. VALDERRÁBANO F: Erythropoietin in chronic renal failure. Kidney Int 50:1373-1391, 1996
19. NISSENSON AR: Hvporesponsiveness to erythropoietin: Overview, Perit Dial Int 16:417-420, 1996
20. TARNG DC, HUANG TP: Hyporesponsiveness to erythropoietin. Perit Dial Int 17:99-100, 1997
21. ESCHBACH JW, KELLY MR, HALEY NR, ABELS RI, ADAMSON JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
22. VAN WYCK DB, STIVELMAN JC, RUTZ J, KIRLIN LF, KATZ MA, OGDEN DA: Iron status in patients receiving erythropoietin for dialysis associated anemia. Kidney Int 35:712-716, 1989
23. MACDOUGALL IC, CAVILL I, HULME B, BAIN B, MCGREGOR E, MCKAY P, SAUDERS E, COLES GA, WILLIAMS JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. BMJ 304:225-226, 1992
24. TARNG DC, CHEN TW, HUANG TP: Iron metabolism indices for early detection of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995
25. ADAMSON JW, ESCHBACH JW: Management of the anemia of chronic renal failure with recombinant erythropoietin. Q J Med 73:1093-1101, 1989
26. MUIRHEAD N, HODSMAN AB: Occult infection and resistance of anaemia to r-HuEpo therapy in renal failure. Nephrol Dial Transplant 5:232-234, 1990
27. COFÁN F, BONAL J, CASTELLOTE E, CARALPS A: Vasculitis in haemodialysis: A new form of resistance to erythropoietin. Nephrol Dial Transplant 8:569-570, 1993
28. ALMOND MK, TAILOR D, KELSEY SM, CUNNINGHAM J: Treatment of erythropoietin resistance with cyclosporin. Lancet 343:916-917, 1994
29. TARNG DC, HUANG TP: Uraemic pericarditis: A reversible inflammatory state of resistance to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 8:569-570, 1993
30. BIA MJ, COOPER K, SCHNALL S, DUFFY T, HENDLER E, MALLUCHE J, SOLOMON L: Aluminium induced anemia: Pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 36:852-858, 1989
31. ROSENLÖF K, FYHRQUIST F, TENHUNEN R: Erythropoietin, aluminium, and anaemia in patients on haemodialysis. Lancet 335:247-249, 1990
32. TARNG DC, HUANG TP: Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: Role of aluminum toxicity. Am J Nephrol 18:1-8, 1998
33. RAO DS, SHIH MS, MOHINI R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175, 1993
34. MACDOUGALL IC, JONES EA, EVANS W, CAVILL I, COLES GA, WILLIAMS JD: Management of occult gastrointestinal blood loss in haemodialysis patients on erythropoietin. Nephrol Dial Transplant 8:959-960, 1993
35. EVANS J: Cardiac hemolysis and anemia refractory to erythropoietin: On anemia induced in dialysis patients. Nephron 71:108-109, 1995
36. STEINBERG MH: Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med 324:1369-1370, 1991
37. TARNG DC, CHANG JG, HUANG TP: Resistance to recombinant erythropoietin in a hemodialysis patient with heterozygous hemoglobinopathy J-Meinung. Am J Kidney Dis 29:769-772, 1997
38. LAI KN, WONG KC, LI PKT, LUI SF: Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis 14:239-245, 1992
39. KAGAN A, SINAY-TRIEMAN L, BAR-KHAYIM Y: Recombinant human erythropoietin for anaemia in thalassaemic minor patients on dialysis. Nephrol Dial Transplant 10:2375-2376, 1995
40. TARNG DC, HUANG TP, CHEN TW, FAN CY, CHANG JG: Resistance to recombinant human erythropoietin treatment in thalassaemic patients on chronic haemodialysis: A real clinical entity? Nephrol Dial Transplant 11:1893-1895, 1996
41. JACOBS A, MILLER F, WORWOOD M, BEAMISH MR, WARDROP CA: Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. BMJ 4:206-208, 1972
42. GOKAL R, MILLARD PR, WEATHERALL DJ, CALLENDER STE, LEDINGHAM JGG, OLIVER DO: Iron metabolism in haemodialysis patients: A study of the management of iron therapy and overload. Q J Med 48:369-391, 1979
43. LYNN KL, MITCHELL TR, SHEPPERD J: Serum ferritin concentration in patients receiving maintenance hemodialysis. Clin Nephrol 14:124-127, 1980
44. BLUMBERG AB, MARTI HRM, GRABER CG: Serum ferritin and bone marrow iron in patients ongoing continuous ambulatory peritoneal dialysis. JAMA 250:3317-3319, 1983
45. BELL JD, KINCAID WR, MORGAN RG, BUNCE H, ALPERIN JB, SARLES HE, REMMERS AR: Serum ferritin assay and bone marrow iron stores in patients on maintenance hemodialysis. Kidney Int 17:237-241, 1981
46. MIRAHMADI KS, PAUL WL, WINER RL, DABIR-VAZIRI N, BYER B, GORMAN JT, ROSEN SM: Serum ferritin level: Determination of iron requirement in hemodialysis patients. JAMA 237:601-603, 1977
47. DOCCI D, TURCI F, SALVI G, CENCIOTTI L, PISTOCCHI E: Serum ferritin in patients on maintenance hemodialysis. Nephron 34:201-202, 1983
48. ALLEGRA V, MENGOZZI G, VASILE A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatment. Nephron 57:175-182, 1991
49. ERSLEV AJ: Erythropoietin. N Engl J Med 324:1339-1344, 1991
50. SCHAEFER RM, SCHAEFER L: Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 3:71-75, 1992
51. SUNDER-PLASSMANN G, HÖRL WH: Iron metabolism and iron substitution during erythropoietin therapy. Clin Invest 72:S11-S15, 1994
52. FISHBANE S, FREI GL, MAESAKA J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
53. ESCHBACH JW: Management of poor responders to erythropoietin therapy, in Satellite Symposium on Erythropoietin, in 11th Asian Colloquium in Nephrology (abstract), Singapore, September 26-30, 1996, p 35
54. BAINTON DF, FINCH CA: The diagnosis of iron deficiency anemia. Am J Med 37:62-70, 1964
55. MACDOUGALL IC, HUTTON RD, CAVILL I, COLES GA, WILLIAMS JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br J Med 299:157-158, 1989
56. CASATI S, CAMPISE M, PONTICELLI C: Correction of anemia with recombinant human erythropoietin despite low serum ferritin. Nephrol Dial Transplant 6:452-456, 1991
57. GRUTZMACHER P, TSOBANELIS T, ROTH P, WERNER E, VLACHO-JANNIS J, KALTWASSER J, KURZ P, SCHEUERMANN EH, SCHOEPPE W: Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: Theoretical consideration, clinical experience and consequences. Clin Nephrol 38(Suppl 1):92-97, 1992
58. HÖRL WH, CAVILL I, MACDOUGALL IC, SCHAEFER RM, SUNDER-PLASSMANN G: How to diagnose and correct iron deficiency during r-HuEPO therapy: A consensus report. Nephrol Dial Transplant 11:246-250, 1996
59. TARNG DC, HUANG TP, CHEN TW: Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Am J Nephrol 17:158-164, 1997
60. BRAUN J, LINDNER K, SCHREIBER M, HEIDLER RA, HÖRL WH: Percentage of hypochromic red cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12:1173-1181, 1997
61. GOLAN E, RADNAY J, GOLDMANN J, BERNHEIM J, RATHAUS M: Relationship between transferrin saturation index and red cell size and haemoglobin content in haemodialysis patients. Nephrol Dial Transplant 9:1030-1031, 1994
62. HASTKA J, LASSERRE JJ, SCHWARZBECK A, HEHLMANN R, STRAUCH M: Zinkprotoporphyrin als Alternative zu Ferritin bei Steuerung der Eisenubstitution Erythropoietin-bedürftiger Dialysepatienten. Nieren Hochdruckkrankh 20:697-700, 1991
63. FISHBANE S, LYNN RI: The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25:426-432, 1995
64. BEGUIN BY, LOOZIK M, R, SAUTOIS S, LEJEUNE B, RORIVE F, FILLET G, EARLY G: Prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82:2010-2016, 1993
65. DANIELSON B: R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 10(Suppl 2):69-73, 1995
66. CARAVACA F, VAGACE JM, APARICIO A, GROISS J, PIZARRO JL, ALONSO N, GARCIA MC, ARROBAS M, CUBERO J, ESPARRAGO J, SANCHEZ-CASADO E: Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy. Am J Kidney Dis 20:249-254, 1992
67. FISHBANE S, MAESAKA JK: Iron management in end-stage renal disease. Am J Kidney Dis 29:319-333, 1997
68. SUNDER-PLASSMANN G, HÖRL WH: Erythropoietin and iron. Clin Nephrol 47:141-157, 1997
69. 1996 Annual Report on the Management of End-Stage Renal Failure in Taiwan: National Dialysis Surveillance Program by Society of Nephrology, Republic of China, pp 1-4
70. O'NEILL-CUTTING MA, CROSBY WH: The effect of antacids on the absorption of simultaneously ingested iron. JAMA 255:1468-1470, 1986
71. LINDSAY RM, BURTON JA, EDWARD N, DARGIE HJ, PRENTICI CRM, KENNEDY AC: Dialyzer blood loss. Clin Nephrol 1:29-34, 1973
72. LONGNECKER RE, GOFFINET JA, HENDLER ED: Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organ 20:135-140, 1974
73. MILMAN N, LARSEN L: Iron absorption in patients with chronic uremia undergoing regular hemodialysis. Acta Med Scand 199:113-119, 1976
74. GOCH J, BIRGEGARD G, DANIELSON BG, WIKSTRÖM B: Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 73:403-406, 1996
75. TINAWI M, MARTIN KJ, BASTANI B: Oral iron absorption test in patients on CAPD: Comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 74:291-294, 1996
76. MACDOUGALL IC, HUTTON RD, GRAVILL I, COLES GA, WILLIAMS JD: Treating renal anemia with recombinant human erythropoietin: Practical guidelines and a clinical algorithm. BMJ 300:655-659, 1990
77. KOOISTRA MP, VAN ES A, STRUYVENBERG A, MARX JJM: Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79:634-639, 1991
78. SUNDER-PLASSMANN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
79. TAYLOR JE, PEAT N, PORTER C, MORGAN AG: Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996
80. SEPANDJ F, JINDAL K, WEST M, HIRSCH D: Economic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996
81. PASCUAL J, TERUEL JL, LIANO F, SUREDA A, ORTUNO J: Sodium rric gluconate complex given intravenously for iron-deficiency in haemodialysis. (letter) Clin Nephrol 35:87, 1991
82. PASCUAL J, TERUEL JL, LIANO F, SUREDA A, ORTUNO J: Intravenous Fe-Gluconate-Na for iron-deficient patients on hemodialysis. Nephron 60:121, 1992
83. ROSENLÖF K, KIVIVUORI SM, GRÖNHAGEN-RISKA C, TEPPO AM, SLIMES MA: Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 43:249-255, 1995
84. WINCHESTER JE, MCGINLEY M, WAHAB A, HALL F, ANDERSON J, BREIFEL G, AUERBACH M: Comparison of 3 iron dextran infusion methods to correct anemia in erythropoietin treated hemodialysis patients. (abstract) J Am Soc Nephrol 6:591, 1995
85. ALI M, FAYEMI AO, RIGILOSI R, FRANCINO J, MARSDEN T, MALCOLM D: Hemosiderosis in hemodialysis patients. JAMA 244:343-345, 1980
86. KOTHARI T, SWAMY AP, LEE JCK, MANGLA JC, CESTERO RVM: Hepatic hemosiderosis in maintenance hemodialysis patients. Dig Dis Sci 25:363-368, 1980
87. TOMSON CRV: Erythropoietin: What problems remain in 1994? Nephrol Dial Transplant 9:344-345, 1994
88. BOELAERT JR, DANEELS RF, SCHURGERS ML, MATTHYS EG, GORDTS BZ, VAS LANDUYT HW: Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 5:130-134, 1990
89. GRANNOLLERAS C, OULES R, SHALDON S, POLLOCK M, BALDAMUS CA, NONNAST-DANIEL B, KOCH KM: Benefit of continuous i.v. iron with erythropoietin therapy in hemodialysis patients. (abstract) Nephrol Dial Transplant 6:824, 1991
90. TSOBANELIS T, HOPPE D, SCIGALLA P, GRÜTZMACHER P: Optimierte Behandlung der renalen Anämie mit kombinierter intravenöser Eisen- und Ultra-low-dose-erythropoietin-substitution. (abstract) Nieren Hochdruckkrankh 20:454, 1991
91. SILVERBERG DS, BLUM M, PEER G, KAPLAN E, IAINA A: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996
92. SILVERBERG DS, IAINA A, PEER G, KAPLAN E, LEVI BA, FRANK N, STEINBRUCH S, BLUM M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
93. NAVARRO JF, TERUEL JL, LIAN̄O F, MARCÉN R, ORTUN̄O J: Effectiveness of intravenous administration of Fe-Gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 16:268-272, 1996
94. BESARAB A: Optimizing epoietin therapy in end-stage renal disease: The cause for subcutaneous administration. Am J Kidney Dis 22(Suppl 1):13-22, 1993
95. MUIRHEAD N, BARGMAN J, BURGESS E, JINDAL KK, LEVIN A, NOLIN L, PARFREY P: Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 26(Suppl 1):1-24, 1995
96. FISHBANE S, MAESAKA JK: Factors predictive of suboptimal iron stores in hemodialysis (HD) patients with normal iron indices. (abstract) J Am Soc Nephrol 6:529, 1995
97. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. V. Inadequate epoetin response. Am J Kidney Dis 30(Suppl 3):S218-S220, 1997
98. PRONAIL W, RIEGLER-KEIL M, SILBERBAUER K, STOCKENHUBER F: Folic acid supplementation improves erythropoietin response. Nephron 71:395-400, 1995
99. 12 levels after erythropoietin treatment. Am J. Nephrol 12:188-191, 1992
100. MUIRHEAD N, HODSMAN AB, HOLLOMBY DJ, CORDY PE: The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 6:342-345, 1991
101. MLADENOVIC J: Aluminium inhibits erythropoiesis in vitro. J Clin Invest 81:1661-1665, 1988
102. DONNELLY SM, ALI MAM, CHURCHILL DN: Bioavailability of iron in hemodialysis patients treated with erythropoietin: Evidence for ibitor, role of aluminium. Am J Kidney Dis 16:447-451, 1990
103. GARBOSSA G, GUTNISKY A, NESSE A: The inhibitory action of aluminium on mouse bone marrow cell growth: Evidence for an erythropoietin- and transferrin-mediated mechanism. Am J Nephrol 20:141-146, 1994
104. TOUAM M, MARTINEZ F, LACOUR B, BOURDON R, ZINGRAFF J, DI GIULIO S, DRÜEKE T: Aluminium-induced reversible microcytic anemia in chronic renal failure: Clinical and experimental studies. Clin Nephrol 19:295-298, 1983
105. SWARTZ R, DOMBROUSKI J, BURNATOWSKA-HLEDIN M, MAYOR G: Microcytic anemia in dialysis patients: Reversible marker of aluminium toxicity. Am J Kidney Dis 9:217-223, 1987
106. CARAMELO CANNATA JB, RODELES MR, FERNÁNDEZ-MARTÍN JL, MOSQUERA JR, MONZÚ B, OUTEIRIN̄O J, BLUM G, ANDREA C, LOPEZ-FARRÉ J, ACUÑA G, GASADO S, HERNANDO L: Mechanisms of aluminium-induced microcytosis: Lessons from accidental aluminium intoxication. Kidney Int 47:164-168, 1995
107. CONSENSUS CONFERENCE OF EDTA-ERA: Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant Suppl 1:1-4, 1993
108. CANNATA JB, FERNÁNDEZ-MARTÍN JL, DÍAZ-LÓPEZ B, ALONSO M, OLAIZOLA I, ACUÑA G, CARAMELO C, ALVAREZ-GRANDE J: Influence of iron stores in the response to the deferoxamine testJ Am Soc Nephrol 7:135-139, 1996
109. COZMA G, COZMA MC, MATTES U: Beneficial effect of recombinant human erythropoietin in beta thalassaemia patients on dialysis. Nephrol Dial Transplant 7:82-83, 1992
110. WINEARLS CG, HUGHES RT, PIPPARD MJ, COTES PM: Erythropoietin dose requirement in a patient with Hb H disease and renal failure. Nephrol Dial Transplant 7:1052-1054, 1992
111. CHENG IKP, LU HB, WEI DC, CHENG SW, CHAN CY, LEE FCP: Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13:142-148, 1993
112. ROGER SD, MACDOUGALL IC, THURAISINGHAM RC, RAINE AGE: Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 325:1175-1176, 1991
113. TOMSON CRV, EDMUNDS ME, CHAMBERS K, BRICKNELL S, FEE, WALLS J: Effects of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7:817-821, 1992
114. ALMOND MK, TAILOR D, MARSH FP, RAFTERY MJ, CUNNINGHAM J: Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 9:270-273, 1994
115. SLIWINSKI AJ, WEBER LD, NASHEL DJ: C-reactive protein v erythrocyte sedimentation rate: A comparison of effectiveness as an infection marker in patients undergoing peritoneal dialysis. Arch Pathol Lab Med 107:387-388, 1983
116. BÁRÁNY P, DIVINO FILHO JC, BERGSTRÖM J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29:565-568, 1997
117. ANASTASSIADES EG, HOWARTH D, HOWARTH J, SHANKS D, WATERS HM, HYDE K, GEARY CG, LIU YIN JA, GOKAL R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993
118. MACDOUGALL IC, TUCKER B, THOMPSON J, TOMSON CR, BAKER LRI, RAINE AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1993
119. ESCHBACH JW, DOWNING MR, EGRIE JC, BROWNE JK, ADAMSON JW: USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 76:160-165, 1989
120. EL-RESHAID K, JOHNY KV, HAKIM A, KAMEL H, SEBETA A, HOURANI H, KANYIKE FB: Erythropoietin treatment in haemodialysis patients with iron overload. Acta Haematol 91:130-135, 1994
121. GASTALDELLO K, VEREERSTRAETEN A, NZAME-NZE T, VANHER-WEGHEM JL, TIELEMANS C: Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10(Suppl 6):44-47, 1995
122. TARNG DC, HUANG TP: Improvement of anemia with ascorbic acid in iron-overloaded hemodialysis patients with hyporesponsiveness to erythropoietin. (abstract) Nephrol 3(Suppl 1):457, 1997
123. COSTELLO JF, SADOVNIC MJ, COTTINGTON EM: Plasma oxalate levels in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1:1289-1298, 1991